Home › Research › Biomarkers
Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia
Constance Delaby, Daniel Andres Alcolea, Germain U. Busto, Audrey Gabelle, Xavier Ayrignac, Karim Bennys, Elena Muiño, Paula Villatoro et al.. Alzheimer s Research & Therapy, 2025-02-13
Topic: Amyloid, tau and blood-test diagnosis
and amyloid composite in the context of AD. In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone. Hepcidin was not significantly modified in CADASIL patients compared to control subjects. Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and implementation of clinical trials.
Key findings
- and amyloid composite in the context of AD.
- In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone.
- Hepcidin was not significantly modified in CADASIL patients compared to control subjects.
- Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD.
- This result could have important implications for diagnosis and implementation of clinical trials.
Why it matters
Blood hepcidin and NfL had limited value for diagnosing Alzheimer's disease but combining them was informative for vascular dementia. This is a diagnostic finding and does not address treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Sylvain Lehmann: h-index 75 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39948603) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-025-01696-9
- PubMed: 39948603
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Delaby, C., Alcolea, D. A., Busto, G. U., Gabelle, A., Ayrignac, X., Bennys, K., et al. (2025). Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01696-9
Vancouver
Delaby C, Alcolea DA, Busto GU, Gabelle A, Ayrignac X, Bennys K, et al. Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01696-9. PMID: 39948603.
BibTeX
@article{delaby2025-39948603,
author = {Delaby, Constance and Alcolea, Daniel Andres and Busto, Germain U. and Gabelle, Audrey and Ayrignac, Xavier and Bennys, Karim and Muiño, Elena and Villatoro, Paula and others},
title = {{Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia}},
journal = {Alzheimer s Research \& Therapy},
year = {2025},
doi = {10.1186/s13195-025-01696-9},
pmid = {39948603},
url = {https://doi.org/10.1186/s13195-025-01696-9}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.